Literature DB >> 8075633

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs.

L L Green1, M C Hardy, C E Maynard-Currie, H Tsuda, D M Louie, M J Mendez, H Abderrahim, M Noguchi, D H Smith, Y Zeng, N E David, H Sasai, D Garza, D G Brenner, J F Hales, R P McGuinness, D J Capon, S Klapholz, A Jakobovits.   

Abstract

We describe a strategy for producing human monoclonal antibodies in mice by introducing large segments of the human heavy and kappa light chain loci contained on yeast artificial chromosomes into the mouse germline. Such mice produce a diverse repertoire of human heavy and light chains, and upon immunization with tetanus toxin have been used to derive antigen-specific, fully human monoclonal antibodies. Breeding such animals with mice engineered by gene targeting to be deficient in mouse immunoglobulin (Ig) production has led to a mouse strain in which high levels of antibodies are produced, mostly comprised of both human heavy and light chains. These strains should provide insight into the adoptive human antibody response and permit the development of fully human monoclonal antibodies with therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075633     DOI: 10.1038/ng0594-13

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  70 in total

1.  Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody.

Authors:  Andrew B Norman; William J Ball
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 2.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

Review 3.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 4.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 5.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 6.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

Review 7.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 8.  Animal pharming, two decades on.

Authors:  Alexander Kind; Angelika Schnieke
Journal:  Transgenic Res       Date:  2008-07-29       Impact factor: 2.788

Review 9.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

Review 10.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.